SARS-CoV-2感染继发急性呼吸衰竭成人患者无创呼吸支持的临床共识推荐
该共识由西班牙重症医学学会(SEMICYUC)、呼吸病学学会(SEPAR)、急诊医学学会(SEMES)和麻醉与复苏及疼痛学会(SEDAR)的多学科专家组制定,基于证据知情指南,针对疑似或确诊COVID-19合并急性呼吸衰竭的成人患者,提供无创通气与经鼻高流量氧疗的无创呼吸支持推荐。共识指出大多数COVID-19患者为轻症,约14%需住院和氧支持,5%需入住ICU;重症可并发ARDS、脓毒症与脓毒性休克及多器官衰竭。该共识旨在为优化支持治疗提供基础,以争取最佳生存机会,并便于在随机对照试验中可靠比较研究性治疗干预。
要点
- 共识适用于疑似或确诊COVID-19合并急性呼吸衰竭的成人患者。
- 共识涵盖的无创呼吸支持方式为无创通气与经鼻高流量氧疗。
- 约14%的COVID-19患者发展为需住院和氧支持的严重疾病,5%需入住ICU。
- 重症COVID-19可并发ARDS、脓毒症与脓毒性休克及多器官衰竭。
- 共识由SEMICYUC、SEPAR、SEMES和SEDAR四个西班牙科学学会的多学科专家组制定。
适用人群与场景
- 任何疑似或确诊COVID-19合并急性呼吸衰竭的成人患者。
处置流程与药物剂量
- 共识提供无创通气与经鼻高流量氧疗的无创呼吸支持临床推荐,适用于疑似或确诊COVID-19合并急性呼吸衰竭的成人患者。
研究设计与关键结果
- 该共识由来自四个西班牙科学学会(SEMICYUC、SEPAR、SEMES、SEDAR)的多学科专家组基于证据知情指南制定,专家具有COVID-19及其他病毒感染(包括SARS)以及脓毒症和ARDS的临床管理经验。
- 共识指出大多数COVID-19患者仅发展为轻度或非复杂疾病,约14%发展为需住院和氧支持的严重疾病,5%需入住ICU。
- 共识指出重症COVID-19可并发ARDS、脓毒症与脓毒性休克及多器官衰竭。
证据类型、等级与局限
- 证据类型:多学科专家共识,基于证据知情指南制定。
- 局限:原文未报告局限性
对床旁实践的改变
- 该共识为疑似或确诊COVID-19合并急性呼吸衰竭的成人患者提供无创通气与经鼻高流量氧疗的无创呼吸支持推荐,旨在作为优化支持治疗的基础。
指南或共识出处
- 西班牙重症医学学会(SEMICYUC)、西班牙呼吸病学学会(SEPAR)、西班牙急诊医学学会(SEMES)、西班牙麻醉与复苏及疼痛学会(SEDAR)临床共识推荐,发表于Rev Esp Anestesiol Reanim (Engl Ed)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials.
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials.
参考来源
- Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné ML, et al. Clinical Consensus Recommendations Regarding Non-Invasive Respiratory Support in the Adult Patient with Acute Respiratory Failure Secondary to SARS-CoV-2 infection. Rev Esp Anestesiol Reanim (Engl Ed). 2020. PMID: 32307151. doi:10.1016/j.redar.2020.03.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。